454 Life Sciences and the Genome Sequencing Center at Washington University School of Medicine in St. Louis Announce Collaborative Research Plan

07 Dec, 2005, 00:00 ET from 454 Life Sciences Corporation from ,CuraGen Corporation

    BRANFORD, Conn., Dec. 7 /PRNewswire-FirstCall/ -- 454 Life Sciences
 Corporation, a majority-owned subsidiary of CuraGen Corporation
 (Nasdaq:   CRGN), and the Genome Sequencing Center (GSC) at Washington
 University School of Medicine in St. Louis today announced a collaborative
 research plan to sequence disease-causing pathogens and to sequence RNA to
 analyze gene activity in tissue samples.  Research will be performed on the
 454 Life Sciences' Genome Sequencer 20 Systems at the GSC.
     Under the first part of the collaborative research plan, scientists at the
 GSC and 454 Life Sciences will utilize the Genome Sequencer 20 System to
 sequence and analyze the genomes of disease-causing pathogens.  By
 understanding the genomic variations among similar pathogens it is hoped that
 clinicians may be able to better diagnose, treat, or prevent infections.
     "Data on small genetic differences between isolates of bacteria, viruses
 and other pathogens can be key to understanding changes in virulence,
 infectivity, antibiotic resistance and other factors important to the control
 and treatment of disease," said Elaine Mardis, co-director of the Genome
 Sequencing Center.  "We will utilize these instrument systems to conduct
 collaborative research with 454 Life Sciences and in production alongside our
 existing technology to generate sequencing data for a variety of ongoing
 projects."
     In a second project, scientists at the GSC, 454 Life Sciences and
 Washington University School of Medicine will use the Genome Sequencer 20 to
 sequence RNA to assess the expression profiles of genes in mammalian cells and
 tissues.  A cell typically uses a fraction of its genes to make proteins at
 any given time and this selective gene expression results in cells taking on
 specialized characteristics.  454 Life Sciences' technology has superior
 sensitivity to enable in-depth studies of RNA and expression profiles, which
 may be useful for identifying novel drug targets and biomarkers for disease
 diagnosis.
     "454 is pleased to have established this collaborative research plan,
 which will initially focus on the sequencing of disease-causing pathogens and
 analysis of gene activity in tissue samples, but could be expanded to
 incorporate additional research topics in the future," stated Christopher K.
 McLeod, President and Chief Executive Officer of 454 Life Sciences.  "The
 Genome Sequencing Center at Washington University is the first research center
 to have purchased a second Genome Sequencer 20 System, further validating the
 use of our technology to better understand the genetic makeup of various
 diseases and to potentially identify those patients who are most likely to
 benefit from a particular treatment."
 
     About The Genome Sequencing Center at Washington University
     The Genome Sequencing Center at Washington University Medical School
 focuses on the generation and analysis of DNA sequence, and played a
 leadership role in The Human Genome Project, constructing the clone map and
 contributing 25 percent of the finished sequence. Focused on genetic research
 with practical applications, the group's more than 250 employees, including 15
 PhD research scientists, have also completed analysis of non-human DNA,
 including the SARS virus, disease-causing bacteria and several animal species.
 
     About 454 Life Sciences
     454 Life Sciences, a 66% majority-owned subsidiary of CuraGen Corporation
 (Nasdaq:   CRGN), is commercializing novel instrumentation and measurement
 services for rapidly and comprehensively conducting high-throughput nucleotide
 sequencing, with specific application to sequencing of whole genomes and
 ultra-deep sequencing of target genes.  454 Life Sciences' Genome Sequencer 20
 System enables one individual to prepare and sequence an entire genome after
 performing a single sample preparation, irrespective of the size of the genome
 being studied.  The hallmark of 454 Life Sciences' technology is the
 PicoTiterPlate(TM), which allows a single instrument using patented light
 emitting sequencing chemistries to produce over 20 million nucleotide bases
 per five-hour run, totaling more than 100 times the capacity of instruments
 using the current macro-scale technology.
 
     The Genome Sequencer 20 System and reagents are available exclusively from
 Roche Applied Sciences.  For additional information on the Genome Sequencer 20
 System and reagents, please visit http://www.roche-applied-
 science.com/sis/sequencing/genome/.  454 Life Sciences offers sequencing
 services directly to customers on a fee for service basis at their state-of-
 the-art Measurement Services Center.  For additional information on 454 Life
 Sciences, please visit http://www.454.com.
 
     Safe Harbor
     This press release contains forward-looking statements that are subject to
 certain risks and uncertainties.  These statements include statements
 concerning 454 Life Sciences' and GSC's plans to sequence disease-causing
 pathogens and to sequence RNA to analyze gene activity in tissue samples; the
 expectation that by understanding the genomic variations among similar
 pathogens, clinicians may be able to better diagnose, treat, or prevent
 infections; the ability of data on small genetic differences between isolates
 of bacteria, viruses and other pathogens to assist in the understanding of
 factors important to the control and treatment of disease; the ability of
 studies of RNA and expression profiles to identify novel drug targets and
 biomarkers for disease diagnosis; the possibility of expansion of research in
 the collaboration; and the ability of 454 Life Sciences' technology to
 identify patients most likely to benefit from a particular treatment.  Such
 statements are based on management's current expectations and are subject to a
 number of risks and uncertainties that could cause actual results to differ
 materially from those described in the forward-looking statements.  454 Life
 Sciences and CuraGen caution investors that there can be no assurance that
 actual results or business conditions will not differ materially from those
 projected or suggested in such forward-looking statements as a result of
 various factors, including, but not limited to, the following: the early stage
 of development of 454 Life Sciences' products and technologies; customer
 acceptance of 454 Life Sciences' products and technologies; 454 Life Sciences'
 ability to scale-up production of its products and technologies; disputes
 between 454 Life Sciences and CuraGen; the success of competing products and
 technologies; technological uncertainty and product development risks;
 uncertainties of clinical trials, government regulation and healthcare reform;
 uncertainty of additional funding with respect to both CuraGen and 454 Life
 Sciences; 454 Life Sciences' and CuraGen's history of incurring losses and the
 uncertainty of achieving profitability; CuraGen's stage of development as a
 biopharmaceutical company; patent infringement claims against 454 Life
 Sciences' and CuraGen's products, processes and technologies; the ability to
 protect 454 Life Sciences' and CuraGen's patents and proprietary rights;
 uncertainties relating to commercialization rights; product liability
 exposure; and competition.  Please refer to CuraGen's Quarterly Report on Form
 10-Q for the period ended September 30, 2005 for a complete description of
 these risks.  454 Life Sciences and CuraGen disclaim any intention or
 obligation to update or revise any forward-looking statements, whether as a
 result of new information, future events, or otherwise, unless required by
 law.
 
 
     454 Life Sciences
     Peter Dacey
     Vice President, Finance
     info@454.com
     (877) 890-GNOM
 
     Noonan Russo
     Robert Stanislaro
     Account Supervisor
     robert.stanislaro@eurorscg.com
     (212) 845-4268
 
 

SOURCE 454 Life Sciences Corporation; CuraGen Corporation
    BRANFORD, Conn., Dec. 7 /PRNewswire-FirstCall/ -- 454 Life Sciences
 Corporation, a majority-owned subsidiary of CuraGen Corporation
 (Nasdaq:   CRGN), and the Genome Sequencing Center (GSC) at Washington
 University School of Medicine in St. Louis today announced a collaborative
 research plan to sequence disease-causing pathogens and to sequence RNA to
 analyze gene activity in tissue samples.  Research will be performed on the
 454 Life Sciences' Genome Sequencer 20 Systems at the GSC.
     Under the first part of the collaborative research plan, scientists at the
 GSC and 454 Life Sciences will utilize the Genome Sequencer 20 System to
 sequence and analyze the genomes of disease-causing pathogens.  By
 understanding the genomic variations among similar pathogens it is hoped that
 clinicians may be able to better diagnose, treat, or prevent infections.
     "Data on small genetic differences between isolates of bacteria, viruses
 and other pathogens can be key to understanding changes in virulence,
 infectivity, antibiotic resistance and other factors important to the control
 and treatment of disease," said Elaine Mardis, co-director of the Genome
 Sequencing Center.  "We will utilize these instrument systems to conduct
 collaborative research with 454 Life Sciences and in production alongside our
 existing technology to generate sequencing data for a variety of ongoing
 projects."
     In a second project, scientists at the GSC, 454 Life Sciences and
 Washington University School of Medicine will use the Genome Sequencer 20 to
 sequence RNA to assess the expression profiles of genes in mammalian cells and
 tissues.  A cell typically uses a fraction of its genes to make proteins at
 any given time and this selective gene expression results in cells taking on
 specialized characteristics.  454 Life Sciences' technology has superior
 sensitivity to enable in-depth studies of RNA and expression profiles, which
 may be useful for identifying novel drug targets and biomarkers for disease
 diagnosis.
     "454 is pleased to have established this collaborative research plan,
 which will initially focus on the sequencing of disease-causing pathogens and
 analysis of gene activity in tissue samples, but could be expanded to
 incorporate additional research topics in the future," stated Christopher K.
 McLeod, President and Chief Executive Officer of 454 Life Sciences.  "The
 Genome Sequencing Center at Washington University is the first research center
 to have purchased a second Genome Sequencer 20 System, further validating the
 use of our technology to better understand the genetic makeup of various
 diseases and to potentially identify those patients who are most likely to
 benefit from a particular treatment."
 
     About The Genome Sequencing Center at Washington University
     The Genome Sequencing Center at Washington University Medical School
 focuses on the generation and analysis of DNA sequence, and played a
 leadership role in The Human Genome Project, constructing the clone map and
 contributing 25 percent of the finished sequence. Focused on genetic research
 with practical applications, the group's more than 250 employees, including 15
 PhD research scientists, have also completed analysis of non-human DNA,
 including the SARS virus, disease-causing bacteria and several animal species.
 
     About 454 Life Sciences
     454 Life Sciences, a 66% majority-owned subsidiary of CuraGen Corporation
 (Nasdaq:   CRGN), is commercializing novel instrumentation and measurement
 services for rapidly and comprehensively conducting high-throughput nucleotide
 sequencing, with specific application to sequencing of whole genomes and
 ultra-deep sequencing of target genes.  454 Life Sciences' Genome Sequencer 20
 System enables one individual to prepare and sequence an entire genome after
 performing a single sample preparation, irrespective of the size of the genome
 being studied.  The hallmark of 454 Life Sciences' technology is the
 PicoTiterPlate(TM), which allows a single instrument using patented light
 emitting sequencing chemistries to produce over 20 million nucleotide bases
 per five-hour run, totaling more than 100 times the capacity of instruments
 using the current macro-scale technology.
 
     The Genome Sequencer 20 System and reagents are available exclusively from
 Roche Applied Sciences.  For additional information on the Genome Sequencer 20
 System and reagents, please visit http://www.roche-applied-
 science.com/sis/sequencing/genome/.  454 Life Sciences offers sequencing
 services directly to customers on a fee for service basis at their state-of-
 the-art Measurement Services Center.  For additional information on 454 Life
 Sciences, please visit http://www.454.com.
 
     Safe Harbor
     This press release contains forward-looking statements that are subject to
 certain risks and uncertainties.  These statements include statements
 concerning 454 Life Sciences' and GSC's plans to sequence disease-causing
 pathogens and to sequence RNA to analyze gene activity in tissue samples; the
 expectation that by understanding the genomic variations among similar
 pathogens, clinicians may be able to better diagnose, treat, or prevent
 infections; the ability of data on small genetic differences between isolates
 of bacteria, viruses and other pathogens to assist in the understanding of
 factors important to the control and treatment of disease; the ability of
 studies of RNA and expression profiles to identify novel drug targets and
 biomarkers for disease diagnosis; the possibility of expansion of research in
 the collaboration; and the ability of 454 Life Sciences' technology to
 identify patients most likely to benefit from a particular treatment.  Such
 statements are based on management's current expectations and are subject to a
 number of risks and uncertainties that could cause actual results to differ
 materially from those described in the forward-looking statements.  454 Life
 Sciences and CuraGen caution investors that there can be no assurance that
 actual results or business conditions will not differ materially from those
 projected or suggested in such forward-looking statements as a result of
 various factors, including, but not limited to, the following: the early stage
 of development of 454 Life Sciences' products and technologies; customer
 acceptance of 454 Life Sciences' products and technologies; 454 Life Sciences'
 ability to scale-up production of its products and technologies; disputes
 between 454 Life Sciences and CuraGen; the success of competing products and
 technologies; technological uncertainty and product development risks;
 uncertainties of clinical trials, government regulation and healthcare reform;
 uncertainty of additional funding with respect to both CuraGen and 454 Life
 Sciences; 454 Life Sciences' and CuraGen's history of incurring losses and the
 uncertainty of achieving profitability; CuraGen's stage of development as a
 biopharmaceutical company; patent infringement claims against 454 Life
 Sciences' and CuraGen's products, processes and technologies; the ability to
 protect 454 Life Sciences' and CuraGen's patents and proprietary rights;
 uncertainties relating to commercialization rights; product liability
 exposure; and competition.  Please refer to CuraGen's Quarterly Report on Form
 10-Q for the period ended September 30, 2005 for a complete description of
 these risks.  454 Life Sciences and CuraGen disclaim any intention or
 obligation to update or revise any forward-looking statements, whether as a
 result of new information, future events, or otherwise, unless required by
 law.
 
 
     454 Life Sciences
     Peter Dacey
     Vice President, Finance
     info@454.com
     (877) 890-GNOM
 
     Noonan Russo
     Robert Stanislaro
     Account Supervisor
     robert.stanislaro@eurorscg.com
     (212) 845-4268
 
 SOURCE  454 Life Sciences Corporation; CuraGen Corporation